AbbVie (ABBV) Stock Insights
ABBV$286.35-0.04 -0.01%
$506.01B
Market Cap
80.80
P/E
20.58
Forward P/E
57
Score
AbbVie (ABBV) Stock Insights
ABBV price $286.35 -0.04 -0.01%
- Ticker
- ABBV
- Price
- $286.35
- Change
- -0.04 -0.01%
- Market cap ?
- $506.01B
- P/E ?
- 80.80
- Forward P/E ?
- 20.58
- Dividend yield ?
- 2.41%
- Beta ?
- 0.28
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stocklytics score
- 57
- Value
- 30
- Quality
- 78
- Growth
- 62
Stocklytics score rationale: value 30, quality 78, growth 62.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 25638000000 | 28216000000 | 32753000000 | 33266000000 | 45804000000 | 56197000000 | 58054000000 | 54318000000 | 56334000000 | 61160000000 |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in…
Fair value
ABBV fair value $433.56. Price $286.35. Price is 34% below fair value.
Above fair value, and more expensive than usual. A larger premium than on 77% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 18.21B. Growth 5.92%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 1.77B. Net debt 63.84B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-10-30 | — | 3.73 | — | 17.32B |
| 2026-07-31 | 3.65 | 3.61 | 16.99B | 16.80B |
| 2026-04-29 | 2.65 | 2.59 | 15.00B | 14.72B |
| 2026-02-04 | 2.71 | 2.65 | 16.62B | 16.41B |
| 2025-10-31 | 1.86 | 1.77 | 15.78B | 15.59B |
| 2025-07-31 | 2.97 | 2.88 | 15.42B | 15.03B |
| 2025-04-25 | 2.46 | 2.38 | 13.34B | 12.93B |
| 2025-01-31 | 2.16 | 2.98 | 15.10B | 14.83B |
| 2024-10-30 | 3.00 | 2.92 | 14.46B | 14.28B |
| 2024-07-25 | 2.65 | 2.57 | 14.46B | 14.02B |
| 2024-04-26 | 2.31 | 2.26 | 12.31B | 11.93B |
| 2024-02-02 | 2.79 | 2.76 | 14.30B | 12.98B |
| 2023-10-27 | 2.95 | 2.86 | 13.93B | 13.67B |
| 2023-07-27 | 2.91 | 2.79 | 13.87B | 13.52B |
| 2023-04-27 | 2.46 | 2.44 | 12.22B | 12.17B |
| 2023-02-09 | 3.60 | 3.54 | 15.12B | 15.33B |
| 2022-10-28 | 3.66 | 3.56 | 14.81B | 14.96B |
| 2022-07-29 | 3.37 | 3.31 | 14.58B | 14.66B |
| 2022-04-29 | 3.24 | 3.14 | 13.54B | 13.61B |
| 2022-02-02 | 3.31 | 3.29 | 14.89B | 14.95B |
| 2021-10-29 | 3.33 | 3.23 | 14.34B | 14.35B |
| 2021-07-30 | 3.11 | 3.11 | 13.96B | 13.96B |
| 2021-04-30 | 2.95 | 2.77 | 13.01B | 12.81B |
| 2021-02-03 | 2.92 | 2.85 | 13.86B | 13.73B |
| 2020-10-30 | 2.83 | 2.75 | 12.90B | 12.63B |
| 2020-07-31 | 2.34 | 2.24 | 10.43B | 9.76B |
| 2020-05-01 | 2.42 | 2.25 | 8.62B | 8.01B |
| 2020-02-07 | 2.21 | 2.19 | 8.70B | 8.63B |
| 2019-11-01 | 2.33 | 2.29 | 8.48B | 8.37B |
| 2019-07-26 | 2.26 | 2.21 | 8.26B | 8.07B |
| 2019-04-25 | 2.14 | 2.05 | 7.83B | 7.50B |
| 2019-01-25 | 1.90 | 1.92 | 8.30B | 8.48B |
| 2018-11-02 | 2.14 | 2.02 | 8.24B | 7.77B |
| 2018-07-27 | 2.00 | 1.98 | 8.28B | 8.15B |
| 2018-04-26 | 1.87 | 1.79 | 7.93B | 7.59B |
| 2018-01-26 | 1.48 | 1.44 | 7.74B | 7.53B |
| 2017-10-27 | 1.41 | 1.39 | 7.00B | 6.90B |
| 2017-07-28 | 1.42 | 1.40 | 6.94B | 6.85B |
| 2017-04-27 | 1.28 | 1.26 | 6.54B | 6.44B |
| 2017-01-27 | 1.20 | 1.20 | 6.80B | 6.80B |
Dividends
Yield 2.42%. Payout ratio 1.90%. Frequency Quarterly.
Safety score 93/100 · Safe. Payout ratio is 2% of earnings. Dividends use a moderate share of free cash flow. Dividends were paid in 14 separate years. Yield is 2.4%, in a range that is usually sustainable.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| 2026-10-15 | $1.73 | 2026-10-15 | 2026-11-16 | Quarterly |
| 2026-07-15 | $1.73 | 2026-07-15 | 2026-08-14 | Quarterly |
| 2026-04-15 | $1.73 | 2026-04-15 | 2026-05-15 | Quarterly |
| 2026-01-16 | $1.73 | 2026-01-16 | 2026-02-17 | Quarterly |
| 2025-10-15 | $1.64 | 2025-10-15 | 2025-11-14 | Quarterly |
| 2025-07-15 | $1.64 | 2025-07-15 | 2025-08-15 | Quarterly |
| 2025-04-15 | $1.64 | 2025-04-15 | 2025-05-15 | Quarterly |
| 2025-01-15 | $1.64 | 2025-01-15 | 2025-02-14 | Quarterly |
| 2024-10-15 | $1.55 | 2024-10-15 | 2024-11-15 | Quarterly |
| 2024-07-15 | $1.55 | 2024-07-15 | 2024-08-15 | Quarterly |
| 2024-04-12 | $1.55 | 2024-04-15 | 2024-05-15 | Quarterly |
| 2024-01-12 | $1.55 | 2024-01-16 | 2024-02-15 | Quarterly |
| 2023-10-12 | $1.48 | 2023-10-13 | 2023-11-15 | Quarterly |
| 2023-07-13 | $1.48 | 2023-07-14 | 2023-08-15 | Quarterly |
| 2023-04-13 | $1.48 | 2023-04-14 | 2023-05-15 | Quarterly |
| 2023-01-12 | $1.48 | 2023-01-13 | 2023-02-15 | Quarterly |
| 2022-10-13 | $1.41 | 2022-10-14 | 2022-11-15 | Quarterly |
| 2022-07-14 | $1.41 | 2022-07-15 | 2022-08-15 | Quarterly |
| 2022-04-13 | $1.41 | 2022-04-15 | 2022-05-16 | Quarterly |
| 2022-01-13 | $1.41 | 2022-01-14 | 2022-02-15 | Quarterly |
| 2021-10-14 | $1.30 | 2021-10-15 | 2021-11-15 | Quarterly |
| 2021-07-14 | $1.30 | 2021-07-15 | 2021-08-16 | Quarterly |
| 2021-04-14 | $1.30 | 2021-04-15 | 2021-05-14 | Quarterly |
| 2021-01-14 | $1.30 | 2021-01-15 | 2021-02-16 | Quarterly |
| 2020-10-14 | $1.18 | 2020-10-15 | 2020-11-16 | Quarterly |
| 2020-07-14 | $1.18 | 2020-07-15 | 2020-08-14 | Quarterly |
| 2020-04-14 | $1.18 | 2020-04-15 | 2020-05-15 | Quarterly |
| 2020-01-14 | $1.18 | 2020-01-15 | 2020-02-14 | Quarterly |
| 2019-10-11 | $1.07 | 2019-10-15 | 2019-11-15 | Quarterly |
| 2019-07-12 | $1.07 | 2019-07-15 | 2019-08-15 | Quarterly |
| 2019-04-12 | $1.07 | 2019-04-15 | 2019-05-15 | Quarterly |
| 2019-01-14 | $1.07 | 2019-01-15 | 2019-02-15 | Quarterly |
| 2018-10-12 | $0.96 | 2018-10-15 | 2018-11-15 | Quarterly |
| 2018-07-12 | $0.96 | 2018-07-13 | 2018-08-15 | Quarterly |
| 2018-04-12 | $0.96 | 2018-04-13 | 2018-05-15 | Quarterly |
| 2018-01-11 | $0.71 | 2018-01-12 | 2018-02-15 | Quarterly |
| 2017-10-12 | $0.64 | 2017-10-13 | 2017-11-15 | Quarterly |
| 2017-07-12 | $0.64 | 2017-07-11 | 2017-08-15 | Quarterly |
| 2017-04-11 | $0.64 | 2017-04-13 | 2017-05-15 | Quarterly |
| 2017-01-11 | $0.64 | 2017-01-13 | 2017-02-15 | Quarterly |
| 2016-10-12 | $0.57 | 2016-10-14 | 2016-11-15 | Quarterly |
| 2016-07-13 | $0.57 | 2016-07-15 | 2016-08-15 | Quarterly |
| 2016-04-13 | $0.57 | 2016-04-15 | 2016-05-16 | Quarterly |
| 2016-01-13 | $0.57 | 2016-01-15 | 2016-02-16 | Quarterly |
| 2015-10-13 | $0.51 | 2015-10-15 | 2015-11-16 | Quarterly |
| 2015-07-13 | $0.51 | 2015-07-15 | 2015-08-14 | Quarterly |
| 2015-04-13 | $0.51 | 2015-04-15 | 2015-05-15 | Quarterly |
| 2015-01-13 | $0.49 | 2015-01-15 | 2015-02-13 | Quarterly |
| 2014-10-10 | $0.42 | 2014-10-15 | 2014-11-17 | Quarterly |
| 2014-07-11 | $0.42 | 2014-07-15 | 2014-08-15 | Quarterly |
| 2014-04-11 | $0.42 | 2014-04-15 | 2014-05-15 | Quarterly |
| 2014-01-13 | $0.40 | 2014-01-15 | 2014-02-14 | Quarterly |
| 2013-10-10 | $0.40 | 2013-10-15 | 2013-11-15 | Quarterly |
| 2013-07-11 | $0.40 | 2013-07-15 | 2013-08-15 | Quarterly |
| 2013-04-11 | $0.40 | 2013-04-15 | 2013-05-15 | Quarterly |
| 2013-01-11 | $0.40 | 2013-01-15 | 2013-02-15 | Quarterly |
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-14 | Carethers John | Other | 0 | — | — |
| 2026-09-30 | Quaggin Susan E | Buy | 59 | $261.59 | 15.43K |
| 2026-09-30 | RAPP EDWARD J | Buy | 129 | $261.59 | 33.75K |
| 2026-08-14 | Donoghoe Nicholas | Buy | 32.71K | $79.02 | 2.58M |
| 2026-08-14 | Donoghoe Nicholas | Sell | 32.71K | $250.00 | 8.18M |
| 2026-08-14 | Donoghoe Nicholas | Sell | 32.71K | $79.02 | 2.58M |
| 2026-06-30 | RAPP EDWARD J | Buy | 134 | $251.64 | 33.72K |
| 2026-06-30 | Quaggin Susan E | Buy | 62 | $251.64 | 15.60K |
| 2026-05-08 | FALK THOMAS J | Buy | 1.12K | — | — |
| 2026-05-08 | WADDELL FREDERICK H | Buy | 1.12K | — | — |
| 2026-05-08 | Roberts Rebecca B | Buy | 1.12K | — | — |
| 2026-05-08 | RAPP EDWARD J | Buy | 1.12K | — | — |
| 2026-05-08 | Quaggin Susan E | Buy | 1.12K | — | — |
| 2026-05-08 | MEYER MELODY B | Buy | 1.12K | — | — |
| 2026-05-08 | Hart Brett J | Buy | 1.12K | — | — |
| 2026-05-08 | FREYMAN THOMAS C | Buy | 1.12K | — | — |
| 2026-05-08 | Davis Jennifer L. | Buy | 1.12K | — | — |
| 2026-05-08 | BURNSIDE WILLIAM H.L. | Buy | 1.12K | — | — |
| 2026-05-08 | AUSTIN ROXANNE S | Buy | 1.12K | — | — |
| 2026-03-31 | Quaggin Susan E | Buy | 71 | $217.49 | 15.44K |
| 2026-03-31 | RAPP EDWARD J | Buy | 155 | $217.49 | 33.71K |
| 2026-03-31 | Alpern Robert J | Buy | 35 | $217.49 | 7.61K |
| 2026-03-04 | Purdue David Ryan | Sell | 5.23K | $233.56 | 1.22M |
| 2026-03-02 | Siatis Perry C | Sell | 5.78K | $233.51 | 1.35M |
| 2026-03-02 | Siatis Perry C | Sell | 10.29K | $234.66 | 2.41M |
| 2026-03-02 | Siatis Perry C | Sell | 2.60K | $235.26 | 611.68K |
| 2026-02-27 | Purdue David Ryan | Sell | 2.11K | $232.08 | 489.22K |
| 2026-02-27 | Crum Demetris D | Sell | 1.59K | $232.08 | 369.94K |
| 2026-02-27 | Thakkar Roopal | Sell | 8.04K | $232.08 | 1.87M |
| 2026-02-27 | Michael Robert A. | Sell | 36.52K | $232.08 | 8.48M |
| 2026-02-27 | Stewart Jeffrey Ryan | Sell | 23.81K | $232.08 | 5.53M |
| 2026-02-27 | Siatis Perry C | Sell | 14.85K | $232.08 | 3.45M |
| 2026-02-27 | Reents Scott T | Sell | 21.64K | $232.08 | 5.02M |
| 2026-02-27 | SALEKI-GERHARDT AZITA | Sell | 16.31K | $232.08 | 3.78M |
| 2026-02-27 | Purdue David Ryan | Sell | 2.69K | $232.08 | 624.76K |
| 2026-02-27 | Donoghoe Nicholas | Sell | 12.87K | $232.08 | 2.99M |
| 2026-02-25 | Siatis Perry C | Buy | 7.29K | $192.86 | 1.41M |
| 2026-02-25 | Siatis Perry C | Buy | 7.78K | $175.28 | 1.36M |
| 2026-02-25 | Siatis Perry C | Buy | 7.31K | $149.62 | 1.09M |
| 2026-02-25 | Siatis Perry C | Sell | 22.38K | $230.00 | 5.15M |
| 2026-02-25 | Siatis Perry C | Sell | 7.29K | $192.86 | 1.41M |
| 2026-02-25 | Siatis Perry C | Sell | 7.78K | $175.28 | 1.36M |
| 2026-02-25 | Siatis Perry C | Sell | 7.31K | $149.62 | 1.09M |
| 2026-02-18 | Thakkar Roopal | Buy | 6.64K | — | — |
| 2026-02-18 | Thakkar Roopal | Buy | 3.35K | — | — |
| 2026-02-18 | Thakkar Roopal | Buy | 2.14K | — | — |
| 2026-02-18 | Thakkar Roopal | Buy | 6.01K | — | — |
| 2026-02-18 | Thakkar Roopal | Buy | 21.94K | $230.04 | 5.05M |
| 2026-02-18 | Purdue David Ryan | Buy | 1.38K | — | — |
| 2026-02-18 | Purdue David Ryan | Buy | 1.29K | — | — |
| 2026-02-18 | Purdue David Ryan | Buy | 890 | — | — |
| 2026-02-18 | Purdue David Ryan | Buy | 2.50K | — | — |
| 2026-02-18 | Purdue David Ryan | Buy | 4.88K | $230.04 | 1.12M |
| 2026-02-18 | Stewart Jeffrey Ryan | Buy | 8.99K | — | — |
| 2026-02-18 | Stewart Jeffrey Ryan | Buy | 9.43K | — | — |
| 2026-02-18 | Stewart Jeffrey Ryan | Buy | 9.27K | — | — |
| 2026-02-18 | Stewart Jeffrey Ryan | Buy | 26.06K | — | — |
| 2026-02-18 | Stewart Jeffrey Ryan | Buy | 26.81K | $230.04 | 6.17M |
| 2026-02-18 | Siatis Perry C | Buy | 5.81K | — | — |
| 2026-02-18 | Siatis Perry C | Buy | 5.63K | — | — |
| 2026-02-18 | Siatis Perry C | Buy | 5.79K | — | — |
| 2026-02-18 | Siatis Perry C | Buy | 16.29K | — | — |
| 2026-02-18 | Siatis Perry C | Buy | 19.50K | $230.04 | 4.49M |
| 2026-02-18 | SALEKI-GERHARDT AZITA | Buy | 6.64K | — | — |
| 2026-02-18 | SALEKI-GERHARDT AZITA | Buy | 7.07K | — | — |
| 2026-02-18 | SALEKI-GERHARDT AZITA | Buy | 6.06K | — | — |
| 2026-02-18 | SALEKI-GERHARDT AZITA | Buy | 17.04K | — | — |
| 2026-02-18 | SALEKI-GERHARDT AZITA | Buy | 20.31K | $230.04 | 4.67M |
| 2026-02-18 | Crum Demetris D | Buy | 13.41K | $230.04 | 3.08M |
| 2026-02-18 | Crum Demetris D | Buy | 1.24K | — | — |
| 2026-02-18 | Crum Demetris D | Buy | 1.22K | — | — |
| 2026-02-18 | Donoghoe Nicholas | Buy | 6.22K | — | — |
| 2026-02-18 | Donoghoe Nicholas | Buy | 5.17K | — | — |
| 2026-02-18 | Donoghoe Nicholas | Buy | 4.63K | — | — |
| 2026-02-18 | Donoghoe Nicholas | Buy | 13.03K | — | — |
| 2026-02-18 | Donoghoe Nicholas | Buy | 20.31K | $230.04 | 4.67M |
| 2026-02-18 | Reents Scott T | Buy | 7.26K | — | — |
| 2026-02-18 | Reents Scott T | Buy | 7.61K | — | — |
| 2026-02-18 | Reents Scott T | Buy | 8.91K | — | — |
| 2026-02-18 | Reents Scott T | Buy | 25.06K | — | — |
| 2026-02-18 | Reents Scott T | Buy | 21.94K | $230.04 | 5.05M |
| 2026-02-18 | Michael Robert A. | Buy | 22.12K | — | — |
| 2026-02-18 | Michael Robert A. | Buy | 14.45K | — | — |
| 2026-02-18 | Michael Robert A. | Buy | 12.03K | — | — |
| 2026-02-18 | Michael Robert A. | Buy | 33.83K | — | — |
| 2026-02-18 | Michael Robert A. | Buy | 81.25K | $230.04 | 18.69M |
| 2025-12-31 | Alpern Robert J | Buy | 34 | $228.49 | 7.77K |
| 2025-12-31 | Quaggin Susan E | Buy | 68 | $228.49 | 15.54K |
| 2025-12-31 | RAPP EDWARD J | Buy | 147 | $228.49 | 33.59K |
| 2025-09-30 | Quaggin Susan E | Buy | 67 | $231.54 | 15.51K |
| 2025-09-30 | Alpern Robert J | Buy | 33 | $231.54 | 7.64K |
| 2025-09-30 | RAPP EDWARD J | Buy | 145 | $231.54 | 33.57K |
| 2025-08-12 | SALEKI-GERHARDT AZITA | Buy | 42.37K | $54.86 | 2.32M |
| 2025-08-12 | SALEKI-GERHARDT AZITA | Sell | 42.37K | $198.42 | 8.41M |
| 2025-08-12 | SALEKI-GERHARDT AZITA | Sell | 42.37K | $54.86 | 2.32M |
| 2025-08-05 | Donoghoe Nicholas | Sell | 3.23K | $198.27 | 641.24K |
| 2025-08-05 | Donoghoe Nicholas | Sell | 10.06K | $198.59 | 2.00M |
| 2025-07-01 | Crum Demetris D | Other | 0 | — | — |
| 2025-07-01 | Crum Demetris D | Other | 4.69K | $192.86 | 903.93K |
| 2025-07-01 | Crum Demetris D | Other | 5.04K | $175.28 | 883.94K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 4.35K, holders +130 vs prior quarter. Ownership 76.07%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| BLACKROCK, INC. | 149.49M | -1.21M | -0.80% | 37.62B |
| VANGUARD CAPITAL MANAGEMENT LLC | 115.40M | 515.77K | +0.45% | 29.04B |
| STATE STREET CORP | 82.60M | 1.38M | +1.70% | 20.78B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 48.48M | -1.05M | -2.11% | 12.20B |
| JPMORGAN CHASE & CO | 47.86M | -8.88M | -15.65% | 12.17B |
| GEODE CAPITAL MANAGEMENT, LLC | 47.00M | 260.85K | +0.56% | 11.81B |
| MORGAN STANLEY | 38.90M | 884.23K | +2.33% | 9.79B |
| CAPITAL RESEARCH GLOBAL INVESTORS | 30.10M | -1.15M | -3.69% | 7.57B |
| NORGES BANK | 25.55M | 25.55M | New | 6.43B |
| BANK OF AMERICA CORP /DE/ | 21.24M | -2.70M | -11.28% | 5.34B |
| FMR LLC | 20.77M | -988.92K | -4.54% | 5.23B |
| NORTHERN TRUST CORP | 20.56M | -652.93K | -3.08% | 5.17B |
| FRANKLIN TEMPLETON INC | 19.93M | 5.37M | +36.92% | 5.01B |
| CAPITAL WORLD INVESTORS | 19.18M | 3.34M | +21.07% | 4.83B |
| GOLDMAN SACHS GROUP INC | 16.29M | 1.15M | +7.57% | 4.10B |
| CAPITAL INTERNATIONAL INVESTORS | 15.64M | 1.22M | +8.46% | 3.94B |
| PRICE T ROWE ASSOCIATES INC /MD/ | 14.75M | 1.75M | +13.42% | 3.71B |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 14.27M | 106.09K | +0.75% | 3.59B |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 12.91M | 12.91M | New | 3.25B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 12.91M | -53.17K | -0.41% | 3.25B |
| BANK OF NEW YORK MELLON CORP | 12.85M | -424.79K | -3.20% | 3.23B |
| UBS GROUP AG | 12.85M | -1.21M | -8.58% | 3.23B |
| LEGAL & GENERAL GROUP PLC | 11.55M | -611.37K | -5.03% | 2.91B |
| AMERIPRISE FINANCIAL INC | 11.52M | 451.20K | +4.08% | 2.90B |
| DEUTSCHE BANK AG\ | 10.77M | 1.24M | +13.03% | 2.71B |
Insights
- Revenue by product
- Revenue by region
| Period | Value |
|---|---|
| FY2013 | Creon: 412000000.0, Duodopa: 178000000.0, Other Products: 1666000000.0 |
| FY2014 | Creon: 516000000.0, Duodopa: 220000000.0, H U M I R A: 12543000000.0, Other Products: 1629000000.0 |
| FY2015 | Creon: 632000000.0, Duodopa: 231000000.0, H U M I R A: 14012000000.0, Imbruvica: 754000000.0, Other Products: 1223000000.0 |
| FY2016 | Creon: 730000000.0, Duodopa: 293000000.0, H U M I R A: 16078000000.0, Imbruvica: 1832000000.0, Other Products: 1217000000.0 |
| FY2017 | Creon: 831000000.0, Duodopa: 355000000.0, H U M I R A: 18427000000.0, Imbruvica: 2573000000.0, Other Products: 998000000.0 |
| FY2018 | Duodopa: 430000000.0, H U M I R A: 19936000000.0, Imbruvica: 3590000000.0, MAVYRET: 3438000000.0, Other Products: 319000000.0, VENCLEXTA: 344000000.0 |
| FY2019 | Duodopa: 461000000.0, H U M I R A: 19169000000.0, Imbruvica: 4674000000.0, MAVYRET: 2893000000.0, Other Products: 511000000.0, RINVOQ: 47000000.0, SKYRIZI: 355000000.0, VENCLEXTA: 792000000.0 |
| FY2020 | Alphagan/Combigan: 326000000.0, Botox Cosmetic: 1112000000.0, Botox Therapeutic: 1387000000.0, Duodopa: 494000000.0, H U M I R A: 19832000000.0, Imbruvica: 5314000000.0, Juvederm Collection: 718000000.0, Linzess/Constella: 667000000.0, Lumigan/Ganfort: 378000000.0, MAVYRET: 1830000000.0, Other Aesthetics: 760000000.0, Other Eye Care: 693000000.0, Other Neuroscience: 539000000.0, Other Products: 2923000000.0, Restasis: 787000000.0, RINVOQ: 731000000.0, SKYRIZI: 1590000000.0, VENCLEXTA: 1337000000.0 |
| FY2021 | Alphagan/Combigan: 529000000.0, Botox Cosmetic: 2232000000.0, Botox Therapeutic: 2451000000.0, Duodopa: 511000000.0, H U M I R A: 20694000000.0, Imbruvica: 5408000000.0, Juvederm Collection: 1535000000.0, Linzess/Constella: 1038000000.0, Lumigan/Ganfort: 579000000.0, MAVYRET: 1710000000.0, Other Aesthetics: 1466000000.0, Other Eye Care: 1169000000.0, Other Neuroscience: 685000000.0, Other Products: 2673000000.0, Restasis: 1290000000.0, RINVOQ: 1651000000.0, SKYRIZI: 2939000000.0, VENCLEXTA: 1820000000.0 |
| FY2022 | Alphagan/Combigan: 346000000.0, Botox Cosmetic: 2615000000.0, Botox Therapeutic: 2719000000.0, Duodopa: 458000000.0, H U M I R A: 21237000000.0, Imbruvica: 4568000000.0, Juvederm Collection: 1428000000.0, Linzess/Constella: 1035000000.0, Lumigan/Ganfort: 514000000.0, MAVYRET: 1541000000.0, Other Aesthetics: 1290000000.0, Other Eye Care: 1175000000.0, Other Neuroscience: 475000000.0, Other Products: 4137000000.0, Restasis: 666000000.0, RINVOQ: 2522000000.0, SKYRIZI: 5165000000.0, VENCLEXTA: 2009000000.0, Vraylar: 2038000000.0 |
| FY2023 | Alphagan/Combigan: 272000000.0, Botox Cosmetic: 2682000000.0, Botox Therapeutic: 2991000000.0, Duodopa: 468000000.0, H U M I R A: 14404000000.0, Imbruvica: 3596000000.0, Juvederm Collection: 1378000000.0, Linzess/Constella: 1108000000.0, Lumigan/Ganfort: 432000000.0, MAVYRET: 1430000000.0, Other Aesthetics: 1234000000.0, Other Eye Care: 803000000.0, Other Neuroscience: 276000000.0, Other Products: 3035000000.0, Ozurdex: 472000000.0, Qulipta: 408000000.0, Restasis: 436000000.0, RINVOQ: 3969000000.0, SKYRIZI: 7763000000.0, Ubrelvy: 815000000.0, VENCLEXTA: 2288000000.0, Vraylar: 2759000000.0 |
| FY2024 | Alphagan/Combigan: 248000000.0, Botox Cosmetic: 2720000000.0, Botox Therapeutic: 3283000000.0, Duodopa: 447000000.0, H U M I R A: 8993000000.0, Imbruvica: 3347000000.0, Juvederm Collection: 1177000000.0, Linzess/Constella: 954000000.0, Lumigan/Ganfort: 429000000.0, MAVYRET: 1311000000.0, Other Aesthetics: 1279000000.0, Other Eye Care: 847000000.0, Other Neuroscience: 338000000.0, Other Products: 3032000000.0, Ozurdex: 494000000.0, Qulipta: 658000000.0, Restasis: 224000000.0, RINVOQ: 5971000000.0, SKYRIZI: 11718000000.0, Ubrelvy: 1006000000.0, VENCLEXTA: 2583000000.0, Vraylar: 3267000000.0 |
| FY2025 | Alphagan/Combigan: 197000000.0, Botox Cosmetic: 2602000000.0, Botox Therapeutic: 3769000000.0, Duodopa: 381000000.0, H U M I R A: 4540000000.0, Imbruvica: 2869000000.0, Juvederm Collection: 993000000.0, Linzess/Constella: 907000000.0, Lumigan/Ganfort: 410000000.0, MAVYRET: 1317000000.0, Other Aesthetics: 1265000000.0, Other Eye Care: 1009000000.0, Other Neuroscience: 207000000.0, Other Products: 2627000000.0, Ozurdex: 493000000.0, Qulipta: 1036000000.0, RINVOQ: 8304000000.0, SKYRIZI: 17562000000.0, Ubrelvy: 1271000000.0, VENCLEXTA: 2792000000.0, Vraylar: 3621000000.0 |
| Period | Value |
|---|---|
| FY2013 | UNITED STATES: 10181000000.0 |
| FY2016 | UNITED STATES: 15947000000.0 |
| FY2017 | UNITED STATES: 18251000000.0 |
| FY2018 | UNITED STATES: 21524000000.0 |
| FY2019 | Non-US: 9359000000.0, UNITED STATES: 23907000000.0 |
| FY2020 | Non-US: 10925000000.0, UNITED STATES: 34879000000.0 |
| FY2021 | Non-US: 12687000000.0, UNITED STATES: 43510000000.0 |
| FY2022 | Non-US: 12341000000.0, UNITED STATES: 45713000000.0 |
| FY2023 | Non-US: 12435000000.0, UNITED STATES: 41883000000.0 |
| FY2024 | Non-US: 13305000000.0, UNITED STATES: 43029000000.0 |
| FY2025 | Non-US: 2364000000.0, UNITED STATES: 46603000000.0 |
Insights · Dividends · Forecast · Financials · Learn